Intrexon Corp Could Rise a Lot According to The Today’s Call Option Activity

 Intrexon Corp Could Rise a Lot According to The Today's Call Option Activity

In today’s session Intrexon Corp (XON) registered an unusually high (276) contracts volume of call trades. Someone, most probably a professional was a very active buyer of the October, 2016 call, expecting serious XON increase. With 276 contracts traded and 35794 open interest for the Oct, 16 contract, it seems this is a quite bullish bet. The option with symbol: XON161021C00033000 closed last at: $0.45 or 28.6% up. About 353,842 shares traded hands. Intrexon Corp (NYSE:XON) has declined 16.40% since March 8, 2016 and is downtrending. It has underperformed by 25.71% the S&P500.

Analysts await Intrexon Corp (NYSE:XON) to report earnings on November, 14. They expect $-0.23 EPS, up 32.35% or $0.11 from last year’s $-0.34 per share. After $-0.29 actual EPS reported by Intrexon Corp for the previous quarter, Wall Street now forecasts -20.69% EPS growth.

Intrexon Corp (NYSE:XON) Ratings Coverage

Out of 6 analysts covering Intrexon (NYSE:XON), 4 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 67% are positive. $70 is the highest target while $28 is the lowest. The $47.40 average target is 58.85% above today’s ($29.84) stock price. Intrexon has been the topic of 10 analyst reports since July 27, 2015 according to StockzIntelligence Inc. Mizuho upgraded Intrexon Corp (NYSE:XON) rating on Wednesday, November 11. Mizuho has “Neutral” rating and $42 price target. JMP Securities initiated the stock with “Market Outperform” rating in Tuesday, May 3 report. The firm earned “Neutral” rating on Wednesday, October 14 by Bank of America. As per Monday, July 27, the company rating was maintained by Wunderlich. The stock of Intrexon Corp (NYSE:XON) earned “Overweight” rating by JP Morgan on Tuesday, August 11. The stock of Intrexon Corp (NYSE:XON) earned “Neutral” rating by Mizuho on Monday, January 25. The stock of Intrexon Corp (NYSE:XON) earned “Underperform” rating by Mizuho on Tuesday, August 11. The company was maintained on Monday, October 19 by Wunderlich. The firm has “Buy” rating by Stifel Nicolaus given on Monday, September 21. The stock of Intrexon Corp (NYSE:XON) earned “Buy” rating by Wunderlich on Tuesday, August 11.

According to Zacks Investment Research, “Intrexon Corporation is a biotechnology company. It provides synthetic biology services. The Company designs and produces modular DNA control systems and applications for human therapeutics, protein production, industrial products, agricultural biotechnology, and animal sciences. Its technologies include the UltraVector gene design and fabrication platform; Cell Systems Informatics; LEAP-cell identification and selection, and mAbLogix-antibody discovery. Intrexon Corporation is based in Germantown, Maryland.”

Insitutional Activity: The institutional sentiment decreased to 1.12 in Q2 2016. Its down 0.22, from 1.34 in 2016Q1. The ratio dropped, as 37 funds sold all Intrexon Corp shares owned while 40 reduced positions. 18 funds bought stakes while 68 increased positions. They now own 98.85 million shares or 1.45% less from 100.31 million shares in 2016Q1.
Franklin Street Advisors Nc holds 10,000 shares or 0.05% of its portfolio. Deutsche Natl Bank Ag last reported 355,954 shares in the company. Manufacturers Life Insurance The reported 3,202 shares or 0% of all its holdings. Hightower Advisors last reported 19,091 shares in the company. Sei Co accumulated 0.02% or 113,366 shares. State Of Wisconsin Investment Board accumulated 36,000 shares or 0% of the stock. Moreover, Swiss Fincl Bank has 0% invested in Intrexon Corp (NYSE:XON) for 94,800 shares. Profund Advsrs Ltd has invested 0.03% of its portfolio in Intrexon Corp (NYSE:XON). Royal Natl Bank Of Canada last reported 22,760 shares in the company. Bluemountain Capital Management Ltd Limited Liability Company owns 30,862 shares or 0.02% of their US portfolio. Addison Com has 0.47% invested in the company for 21,017 shares. State Bank Of Montreal Can holds 0% or 400 shares in its portfolio. New York State Common Retirement Fund last reported 258,615 shares in the company. Cambridge Investment Advsrs Inc holds 0.04% or 73,497 shares in its portfolio. Columbus Circle Investors holds 0.01% or 54,209 shares in its portfolio.

Insider Transactions: Since May 13, 2016, the stock had 2 insider buys, and 0 sales for $1.11 million net activity. $104,484 worth of shares were bought by Nimrodi Nir on Monday, August 29. KIRK RANDAL J also bought $1.00 million worth of Intrexon Corp (NYSE:XON) shares.

Intrexon Corporation forms collaborations to create biologically based products and processes using synthetic biology. The company has a market cap of $3.63 billion. The Firm designs, manufactures and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components. It currently has negative earnings. The Company’s synthetic biology capabilities include the ability to control the amount, location and modification of biological molecules to control the function and output of living cells and optimize for desired results at an industrial scale.

XON Company Profile

Intrexon Corporation (Intrexon), incorporated on June 1, 2010, forms collaborations to create biologically based products and processes using synthetic biology. The Company’s domestic activities are in California, Florida, Maryland, and Virginia, and its primary international activities are in Belgium and Hungary. The Firm designs, manufactures and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components. The Company’s synthetic biology capabilities include the ability to control the amount, location and modification of biological molecules to control the function and output of living cells and optimize for desired results at an industrial scale. The Company’s technologies combine the principles of precision engineering, statistical modeling, automation and production at an industrial scale. The Company’s technologies include UltraVector gene design and fabrication platform, and its associated library of modular DNA components; Cell Systems Informatics; RheoSwitch inducible gene switch; AttSite Recombinases; Protein Engineering; Laser-Enabled Analysis and Processing, or LEAP, and ActoBiotics platform.

More recent Intrexon Corp (NYSE:XON) news were published by: Prnewswire.com which released: “Purcell Julie & Lefkowitz LLP Is Investigating Intrexon Corporation for …” on September 01, 2016. Also Nasdaq.com published the news titled: “Intrexon Corp Breaks Above 200-Day Moving Average – Bullish for XON” on October 03, 2016. Fool.com‘s news article titled: “Here’s Why Intrexon Gained 14.2% in September” with publication date: October 10, 2016 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment